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SUMMARY
The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus
disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally admin-
istered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-
SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper
and lower respiratory tracts ofmice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor.
Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus
macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by
combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-
CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper
and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in
non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in hu-
mans.
INTRODUCTION
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-
2) was first isolated in late 2019 from patients with severe
respiratory illness in China.1 SARS-CoV-2 infection results in a
clinical syndrome, coronavirus disease 2019 (COVID-19), that
can progress to respiratory failure2 and systemic inflammatory
disease.3–5 The elderly, immunocompromised, and those with
comorbidities (e.g., obesity, diabetes, hypertension) are at
greatest risk of death from COVID-19.6 Virtually all countries
and territories have been affected, with more than 125 million in-
fections and 2.7 million deaths recorded worldwide (https://
covid19.who.int/). The rapid expansion and prolonged nature
of the COVID-19 pandemic and its accompanying morbidity,
mortality, and destabilizing socioeconomic effects have made
the development and deployment of a SARS-CoV-2 vaccine an
urgent global health priority.
The spike (S) protein of the SARS-CoV-2 virion engages the
cell-surface receptor angiotensin-converting enzyme 2 (ACE2)
to promote coronavirus entry into human cells.7 Because the S
protein is critical for viral entry, it has been targeted for vaccine
development and therapeutic antibody interventions. SARS-
CoV-2 S proteins are cleaved to yield S1 and S2 fragments, fol-
lowed by further processing of S2 to yield a smaller S20 protein.8
The S1 protein includes the receptor-binding domain (RBD), and
the S2 protein promotesmembrane fusion. The prefusion form of
the SARS-CoV-2 S protein,9 which displays the RBD in an ‘‘up’’
position, is recognized by potently neutralizing monoclonal anti-
bodies10–14 or protein inhibitors.15
Multiple academic and industry groups are developing vac-
cines that target the SARS-CoV-2 S protein16 using several plat-
forms, including DNA plasmid, lipid nanoparticle-encapsulated
mRNA, inactivated virion, subunit, and viral-vectored vac-
cines,17 with most requiring two doses. While several vaccines
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are in advanced clinical trials in humans to evaluate safety and
efficacy, those granted emergency use authorization (Pfizer/Bio-
NTech BNT162b2 andModerna 1273 mRNA18,19 and Johnson &
Johnson Ad26.COV2 and AstraZeneca ChAdOx1 nCoV-19
adenoviral20,21 platforms) are administered by intramuscular in-
jection, resulting in robust systemic yet uncertain mucosal im-
munity. Thus, questions remain as to the ability of these vaccines
to curtail both transmission and severe disease, especially if up-
per airway infection is not prevented or reduced. While many of
the intramuscular vaccines prevent SARS-CoV-2-induced pneu-
monia in non-human primates, they variably protect against up-
per airway infection and, presumably, transmission.22–25
We recently described a chimpanzee adenovirus (simian Ad-
36)-based SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S) en-
coding for the S protein. Intranasal administration of a single
dose of ChAd-SARS-CoV-2-S induced robust humoral and
cell-mediated immune responses against the S protein and
prevented upper and lower airway infection in mice expressing
the human ACE2 receptor.26 This vaccine differs from ChA-
dOx1 nCoV-19, a chimpanzee Ad-23-based SARS-CoV-2 vac-
cine that is currently under Phase III evaluation in humans as
intramuscular injections (NCT04324606) and granted emer-
gency use approval in some countries. ChAd-SARS-CoV-2-S
is derived from a different ChAd serotype, has further deletions
in the backbone to enhance production, and introduces proline
mutations to stabilize the S protein into a pre-fusion form.26
Here, as a next step toward clinical development of ChAd-
SARS-CoV-2-S, we immunized rhesus macaques (Macacamu-
latta) with a single intranasal dose of ChAd-Control or ChAd-
SARS-CoV-2-S, and then challenged animals 1 month later
with SARS-CoV-2 via the combined intranasal and intrabron-
chial routes. Immunization with ChAd-SARS-CoV-2-S resulted
in the development of anti-S, anti-RBD, and neutralizing anti-
bodies as well as T cell responses that prevented or limited
infection in nasal swabs, bronchoalveolar lavage fluid, and
lung tissues after SARS-CoV-2 challenge. Thus, the administra-
tion of a single dose of ChAd-SARS-CoV-2-S vaccine through a
non-injection route has the potential to protect at the portal of
entry and in distant tissues, which could limit both virus-
induced disease and transmission.
Figure 1. Immunogenicity of ChAd-SARS-CoV-2-S in RMs
(A) RMs (3–11 years old) were immunized via intranasal route with a single dose (1011 virus particles) of ChAd-Control or ChAd-SARS-CoV-2-S vaccine. Antibody
responses in sera of immunized RMs at day 28 (day of immunization) and at day 7 (3 weeks after immunization) were evaluated.
(B–E) An ELISA measured anti-S and RBD IgG (B and C) and IgA (D) levels, and a focus neutralization reduction test (FRNT) determined neutralization activity (E)
(n = 6 per group; Mann-Whitney test: **p < 0.01). Bars and columns show median values, and dotted lines indicate the limit of detection (LOD) of the assays.
(F) T cell response. PBMCs were isolated at day14, and SARS-CoV-2-specific T cells were quantified by counting IFN-g+ spots following stimulation with a 15-
mer SARS-CoV-2 S peptide pool (2 mg/mL). Spot-forming unit counts per 106 stimulated PBMCs after deduction of background counts are shown (n = 6; Mann-
Whitney test: *p < 0.05).
See also Figure S1.




Figure 2. Viral RNA levels in the upper respiratory tract of RMs after SARS-CoV-2 challenge
RMs (3–11 years old) were immunized via intranasal route with ChAd-Control or ChAd-SARS-CoV-2-S. Four weeks later, RMs were challenged with 13 106 50%
tissue culture infective dose (TCID50) of SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020) split between the intranasal and intrabronchial administration routes.
(A) Clinical scores after challenge. Boxes show the 25th–75th percentiles, the center lines represent the median, and the extended whiskers from boxes indicate
the minimum/maximum values.
(B–E) Nasal swabs were collected at days +1, +3, +5, and +7. Viral RNAwasmeasured by qRT-PCR using primers specific for subgenomicmRNA (N gene) (B and
D) or genomic RNA (nsp12 gene) (C and E) (n = 6,Mann-Whitney test: *p < 0.05; **p < 0.01; ns, not significant). (D and E) Longitudinal analysis of SARS-CoV-2 viral
RNA in nasal swabs as determined by qRT-PCR showing the subgenomic (D) and genomic RNA (E). Each connected line shows the viral RNA in individual animals
at the indicated time points.
(F) Levels of infectious virus (TCID50 analysis) recovered from nasal swabs of RM obtained 1 day after SARS-CoV-2 challenge (n = 6, Mann-Whitney test). Column
heights (B, C, and F) indicate median values. The dotted line represents the LOD of the assay in this figure.
See also Table S1.






We immunized 12 adult rhesus macaques (RMs, Indian origin),
aged 3 to 11 years old, with ChAd-Control or ChAd-SARS-
CoV-2-S (n = 6 each; 3 females, 3 males). RMs received a single
immunization of 1011 viral particles of the ChAd vectors by the
intranasal route without adjuvant at day 28 (Figure 1A). All of
the animals were pre-screened for the absence of neutralizing
antibody responses against the simian AdV vector (Figure S1)
as well as against SARS-CoV-2. Three weeks after vaccination
(day 7), we detected immunoglobulin G (IgG) antibodies
against the S and RBD proteins by ELISA in all RMs immunized
with ChAd-SARS-CoV-2-S but not ChAd-Control vaccines (Fig-
ures 1B and 1C). We also detected low levels of SARS-CoV-2-
specifc IgA in serum at this time point (Figure 1D). Neutralizing
antibody responses were assessed using an infectious SARS-
CoV-2 focus-reduction neutralization test27 and were detected
in all RMs immunized with ChAd-SARS-CoV-2-S (Figure 1E).
T cell responses specific to SARS-CoV-2 S were assessed by
an interferon-g (IFN-g) ELISpot assay on peripheral bloodmono-
nuclear cells (PBMCs) isolated 2 weeks after vaccination (day
14). All RMs immunized with ChAd-SARS-CoV-2-S but not
ChAd-Control developed T cell responses to SARS-CoV-2 S
(Figure 1F).
Efficacy of ChAd-SARS-CoV-2-S in the upper respiratory
tract
At 4 weeks after immunization, RMs were challenged with 1 3
106 50% tissue culture infective dose (TCID50) of SARS-CoV-2
(strain 2019 n-CoV/USA_WA1/2020) split between intranasal
and intrabronchial routes of administration. The combined chal-
lenge route includes the direct infection of the bronchial tree;
while not optimal for assaying vaccines that induce mucosal im-
munity in the upper airway, this protocol was required since
intranasal infection by itself does not cause consistent lung
infection in RMs.28,29 Even though clinical disease is limited in
SARS-CoV-2-infected RMs,29,30 it was less in animals immu-
nized with ChAd-SARS-CoV-2-S than ChAd-Control vaccine
(Figure 2A; Table S1). Viral loads in the nasal swabs at
days +1, +3, +5, and +7 were measured by quantitative reverse
transcription-PCR (qRT-PCR) using primers for subgenomic (N
gene, subgenomic RNA ) or genomic (nsp12) RNA; the use of
both primer sets allows for distinction of actively replicating virus
(subgenomic RNA) versus input and packaged virus (genomic
RNA). Whereas most of the RMs immunized with ChAd-Control
vaccine showed high levels of viral RNA through day +5 with
some animals persisting through day +7, lower levels were
observed in RMs immunized with ChAd-SARS-CoV-2-S (Figures
2B–2E). At day +1, only one RM vaccinated with ChAd-SARS-
CoV-2-S showed detectable infectious virus in nasal swabs by
a TCID50 assay, whereas 4 of 6 RMs immunized with ChAd-Con-
trol were positive (Figure 2F). At later time points, infectious virus
was not recovered from the nasal swabs of vaccinated animals.
Overall, our data suggest that ChAd-SARS-CoV-2-S vaccine
protects the nasopharyngeal region from SARS-CoV-2 infection
and results in reduced viral RNA levels and accelerated
clearance.
Efficacy of ChAd-SARS-CoV-2-S in the lower respiratory
tract
We next evaluated protective effects in the lower respiratory
tract bymeasuring infection in bronchoalveolar lavage (BAL) fluid
at days +1 and +3 and in lung tissues at day +7. For the BAL fluid
obtained at day +1, all of the samples from ChAd-Control immu-
nized RMs were positive for infectious virus, with titers reaching
as high as 105 TCID/mL, whereas only 1 of 6 samples fromChAd-
SARS-CoV-2-S-immunized animals was positive, with a lower
titer of 4 3 102 TCID/mL (Table 1). At day +3, only 1 (from
ChAd-control immunized RMs) of the 12 BAL fluid samples
collected was positive for infectious virus. Consistent with these
results, at days +1 and +3, substantially higher levels (100- and
50-fold, respectively) of viral RNA were detected in the BAL fluid
of RMs immunized with ChAd-control compared to ChAd-
SARS-CoV-2-S (Figures 3A and 3B).
At day +7, all of the animals were euthanized, and tissues were
collected. Viral RNA was detected in the cervical lymph nodes
(LNs), mediastinal LNs, and the lung tissues in the majority of
ChAd-Control vaccinated animals. However, in ChAd-SARS-
CoV-2-S-immunized animals, lower, if any, viral RNA was de-
tected (Figure 3C). The viral RNA levels in the combined lung
lobes from all of the ChAd-SARS-CoV-2-S-immunized animals
were substantially lower than those measured in ChAd-Con-
trol-immunized animals (Figure 3D). To begin to establish corre-
lates of protection, the viral RNA levels in BAL fluid at day +3
were compared to the serum-neutralizing or anti-S IgG titers
obtained 3 weeks after immunization. We observed an inverse
correlation between viral RNA levels in BAL fluid obtained
3 days after SARS-CoV-2 challenge and neutralizing antibody ti-
ters (Figure 3E). The neutralizing antibody levels correlated better
than the anti-S IgG levels (p = 0.029, R2 = 0.74 versus p = 0.21,
R2 = 0.36, respectively) (Figures 3E and 3F). Thus, serum-
neutralizing antibody titers may serve as a correlate of protection
for the ChAd-SARS-CoV-2-S vaccine. To determine whether
antibody activity in sera could be boosted, we collected sera
Table 1. Virus isolation from BAL fluid
Vaccine RM no. BAL day 1 BAL day 3












, negative; +, <102 TCID50/mL; ++, 102–104 TCID50/mL; +++, 105
TCID50/mL; BAL, bronchoalveolar lavage; RM, rhesus macaque; and
TCID50, tissue culture infectious dose 50.




Figure 3. Viral RNA levels in lower respiratory tracts of RMs after SARS-CoV-2 challenge
RMs (3–11 years old) immunized with ChAd-SARS-CoV-2-S or ChAd-Control were challenged with SARS-CoV-2, as described in Figure 2.
(A and B) BAL fluid was collected at days +1 and +3, and viral subgenomic (A) and genomic (B) RNA levels were assessed in BAL fluids by qRT-PCR (n = 6, Mann-
Whitney test: *p < 0.05; **p < 0.01).
(legend continued on next page)




from ChAd-SARS-CoV-2-S-immunized RMs at day +7 after
SARS-CoV-2 challenge. We observed an ~10-fold increase in
serum-neutralizing titers (Figure 3G) compared to those
measured 1 week before challenge (see Figure 1E). At this time
point, we also observed substantially higher levels of anti-
SARS-CoV-2 IgA in RMs that had been vaccinated with ChAd-
SARS-CoV-2-S (Figure 3H). These findings suggest that a
booster dose of ChAd-SARS-Cov-2-S may enhance the
serum-neutralizing antibody, mucosal immunity, and protective
activity.
Pathological analysis of lungs from vaccinated RMs
In this particular set of challenge experiments, infection in RMs
was mild, and chest radiographs did not show evidence of frank
consolidative pneumonia. ChAd-Control-vaccinated RMs devel-
oped changes consistent with mild pulmonary disease
(Figure 4A). In two animals, we observed marked interstitial
pneumonia characterized by small foci of alveolar septae, thick-
ened by edema fluid and fibrin, with evidence of macrophage
and neutrophil infiltration. Adjacent alveoli contained small
numbers of foamy pulmonary macrophages and rare neutrophils
and were occasionally lined by small numbers of type II pneumo-
cytes. Perivascular infiltrates with small numbers of lymphocytes
forming perivascular cuffs were observed. Immunohistochem-
istry revealed that 4 of the 6 ChAd-Control RMs were positive
for viral antigen that principally localized to type I pneumocytes
(Figure 4B). Two ChAd-SARS-CoV-2-S-vaccinated RMs also
showed small microscopic pulmonary lesions that were similar
to those in the ChAd-Control animals (Figure 4A). Notwith-
standing these findings, none of the ChAd-SARS-CoV-2-S-
vaccinated RMs showed evidence of viral antigen staining in
lung tissues as analyzed by immunohistochemistry (Figure 4B).
DISCUSSION
In this study, we show that in RMs, a single intranasal immuniza-
tion of ChAd-SARS-CoV-2-S confers protection in both the upper
and lower airways against challenge with a high dose of SARS-
CoV-2. These results are consistent with recent studies showing
protection against SARS-CoV-2 challenge after a similar immuni-
zation strategy in mice expressing human ACE2 (hACE2) recep-
tors26 and in hamsters.31Within 3 weeks of intranasal vaccination,
we detected S protein-specific T cell responses in PBMCs as well
as anti-S IgG and IgA, anti-RBD, and neutralizing antibodies in
serum. Immunization with ChAd-SARS-CoV-2-S compared to
the control ChAd-Control vaccine resulted in more rapid clear-
ance of SARS-CoV-2 RNA from nasal samples, decreased levels
of viral RNA in BAL fluid, and lower levels of viral RNA in the ho-
mogenates from different regions of the lungs.
Our experiments showing protection against SARS-CoV-2
infection and pathogenesis in RMs are consistent with other
studies in nonhuman primates using similar or distinct vaccine
platforms. These include: (1) a 3-dose intramuscular vaccination
regimen with whole inactivated SARS-CoV-2, which protected
RM from SARS-CoV-2-induced pneumonia32; (2) a 2-dose intra-
muscular vaccination regimen with a DNA vaccine encoding the
S protein, which reduced viral RNA levels in BAL fluid and nasal
swabs25; (3) a priming or 2-dose intramuscular immunization
with ChAdOx1 nCoV-19, a related chimpanzee adenoviral vec-
tor, resulted in reduced viral loads in BAL fluid and lung tissues
without protection against upper airway infection23; (4) intramus-
cular immunization with a single-dose human Ad26 adenoviral
vector provided near-complete protection in BAL fluid and nasal
swabs after SARS-CoV-2 challenge,22 although viral RNA levels
in lung tissues were not measured; and (5) 1 month after intra-
nasal or intramuscular vaccination with a human Ad5 adenoviral
vector, RMs were protected against SARS-CoV-2 challenge as
evidenced by decreased viral RNA levels in oropharyngeal
swabs and lung tissues.33While all of these studies showprotec-
tion in the RM model, it is nonetheless challenging to compare
them directly because of the following disparities: RMs of
different origin, different immunization and challenge protocols,
different viral stocks and inoculation doses, different clinical
and pathological scoring systems, separate assays for readout
of infection, and different study locations. Moreover, the RM
model generally shows less lung disease after SARS-CoV-2
infection than other animal models (e.g., hACE2 transgenic
mice, mouse-adapted strains and wild-type mice, and ham-
sters), making it more difficult to establish conclusively vaccine
protection against severe disease. The single intranasal immuni-
zation of ChAd-SARS-CoV-2-S in NHPs in this study conferred
virological protection that was comparable to other viral-
vectored vaccines administered to NHPs via intramuscular
routes.22,23,33
The serum neutralization titers at 21 days with a single intra-
nasal dose of ChAd-SARS-CoV-2-S were similar to those ob-
tained with other 1- or 2-dose intramuscular vaccine platforms
in RMs. However, these levels are lower than what we observed
in BALB/c or C57BL/6 mice immunized with a single dose of
ChAd-SARS-CoV-2-S.26 The basis for this discrepancy remains
uncertain, although higher doses on a viral particle per kilogram
were used in mice. As reported recently by others, the relatively
modest levels of immune response in RMs after intranasal
vaccination of adenoviral vectors still conferred effective
protection against SARS-CoV-2,33 and our data show that
serum-neutralizing antibody levels are a reasonable correlate
of protection. These results are consistent with a recent study
establishing serum antibody as a correlate of protection against
(C and D) Tissue samples from different lung lobes, mediastinal LNs, and cervical LNs were collected at day +7 after challenge. Subgenomic viral RNA levels were
assessed by qRT-PCR (C). Viral RNA levels of the combined lung lobe specimens from ChAd-Control or ChAd-SARS-CoV-2-S-immunized RMs are shown (D)
(n = 6, Mann-Whitney test: *p < 0.05; **p < 0.01; ****p < 0.0001).
(E and F) Correlation analysis of serum neutralizing antibody titers (E) and anti-S antibody levels (F) in vaccinated RMs at 3 weeks post-immunization with viral
RNA levels in BAL at day 3 after challenge. The black lines represent the linear regression fit (n = 6, Spearman correlation test: P and r2 values shown).
(G and H) Neutralizing antibody (G) and anti-S IgA (H) responses were evaluated from serum of ChAd-SARS-CoV-2-S-immunized RMs collected at day +7 after
SARS-CoV-2 challenge (n = 6, Mann-Whitney test: **p < 0.01).
Column heights (A–D, G, and H) indicate median values. Dotted lines represent the LOD of the assays. See also Table S1.




SARS-CoV-2 infection in RMs.34 In comparison, others have
used anti-RBD responses in convalescent plasma from humans
to predict protective immunity.35 We also observed T cell re-
sponses to SARS-CoV-2 after vaccination, which also could
contribute to protection.36 Future vaccine dose-response anal-
ysis in RM could provide further insight into the correlates of
protection and potential ways to enhance the humoral and
cellular responses against SARS-CoV-2. Alternatively, a homol-
ogous intranasal or intramuscular booster dose37 with ChAd-
SARS-CoV-2-S or a heterologous adenoviral vector could
augment immune responses and protection. Finally, a different
intranasal vaccine formulation such as spray installation could
also improve protective immune responses.
Vaccines for COVID-19 should protect against pneumonia and
death and curtail transmission in the population. Our preclinical
data in mice,26 hamsters,31 and RMs suggest that ChAd-SARS-
CoV-2-S may accomplish these goals, given its ability to reduce
levels of subgenomic SARS-CoV-2 RNA and infectious virus in
the BAL fluid and lungs and diminish infection at nasopharyngeal
portal sites.We challengedRMswith a high dose of virus (13 106
TCID50) using 2 routes (intranasal and intrabronchial) to test the
efficacy of the vaccine. As this likely does not reflect the exposure
pattern in humans, the ChAd-SARS-CoV-2-S vaccine may show
better efficacy. The direct intrabronchial inoculation of SARS-
CoV-2 used in our challengemodel, which is necessary to estab-
lish consistent pulmonary infection,28,29 likely bypassed the nasal
and pharyngeal mucosal immune barrier and limited the protec-
tive impact of the intranasal vaccine.
In contrast to results with SARS-CoV vaccines or anti-
bodies,38–40 no enhanced infection, immunopathology, or
enhanced disease in animals immunized with the ChAd-SARS-
CoV-2-S vaccine were observed in our study. In the ChAd-
SARS-CoV-2-S vaccinated and challenged RMs, we did not
observe worsening in clinical signs or enhanced replication
compared to controls at any time point in the study. Moreover,
the pathological analysis did not show evidence of the enhanced
immune cell infiltration or alveolar damage seen in the pulmonary
tissues of vaccinated, SARS-CoV challenged RMs.
Limitations of the study
We acknowledge several limitations in this study: (1) we did not
perform direct immunogenicity and efficacy comparisons with
Figure 4. Pathological analysis of lungs of vaccinated RMs
RMs were immunized with ChAd-control and ChAd-SARS-CoV-2-S and challenged following the scheme described in Figure 2. Lungs were harvested at 7 days
post-infection (dpi).
(A) Sections were stained with hematoxylin and eosin and imaged. Each image is representative of a group of 6 RMs.
(B) SARS-CoV-2 antigen was detected in lung sections from RMs for conditions described in (A). Images show low- (left; scale bars, 500 mm), medium- (center;
scale bars, 100 mm), and high-power magnification (right; scale bars, 50 mm). Representative images from n = 6 RMs per group.




intramuscular delivery of ChAd-SARS-CoV-2-S; (2) the differen-
tial effect of route of vaccine administration on protection that we
observed in mice and hamsters26,31 may not directly translate to
primates; (3) we did not assess the durability of immune re-
sponses—future longitudinal studies must be conducted to
monitor immune responses over time after intranasal vaccination
with ChAd-SARS-CoV-2-S to establish durability; and (4) even
with a high dose and invasive route of challenge, many of the
control vaccinated animals did not develop severe lung pathol-
ogy or disease, which limited our ability to evaluate protection
against disease in this model.
In summary, our studies establish that the immunization of pri-
mates with ChAd-SARS-CoV-2-S induces neutralizing antibody
and protective immune responses in both the upper and lower
respiratory tracts. While several vaccine candidates (mRNA,
inactivated, viral vectored) are in advanced phases of human
clinical trials or recently granted emergency use authorization
for the immunization of humans, their efficacy in curtailing trans-
mission remains to be established. Based on preclinical data in
multiple animal models, we suggest that intranasal delivery of
ChAd-SARS-CoV-2-S or possibly other viral-vectored or sub-
unit-based vaccines is a promising platform for preventing
SARS-CoV-2 infection, disease, and transmission, and warrants
further evaluation in humans.
STAR+METHODS
Detailed methods are provided in the online version of this paper
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Data and code availability
All data supporting the findings of this study are available within the paper and are available from the corresponding author upon
request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses and cells
Vero E6 (CRL-1586, American Type Culture Collection (ATCC), andHEK293 cells were cultured at 37C in Dulbecco’s Modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mMHEPES pH 7.3, 1 mM sodium pyruvate, 1X non-essential
amino acids, and 100 U/ml of penicillin–streptomycin. SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was kindly provided by the
Centers for Disease Control and Prevention as a passage 3 stock. The virus was propagated once more in Vero E6 cells in DMEM
(Sigma) supplemented with 2% fetal bovine serum (GIBCO), 1 mM L-glutamine (GIBCO), 50 U/ml penicillin and 50 mg/ml of strepto-
mycin (GIBCO). The virus stock used was passage 4, free of mycoplasma contamination, and identical to the initial deposited Gen-
Bank sequence (MN985325.1).
RM experiments
Experiments with RMs were approved by the Institutional Biosafety and Rocky Mountain Laboratories (NIAID, NIH) Animal Care and
Use Committees. Twelve healthy rhesus macaques (Macaca mulatta; Indian origin, between 3 and 11 years of age and 4 – 10 kg in
weight) were divided randomly into two groups of 6 animals (3 females and 3 males). All macaques were immunized 28 days prior to
challenge by the intranasal route with a total dose of 1011 viral particles of ChAd-Control or ChAd-SARS-CoV-2-S in a total volume of
1 mL (0.5 mL into each nostril). Challenge was performed with a total dose of 1 x106 TCID50 of SARS-CoV-2 equally split between the
two routes in a total volume of 5 mL (4 mL intrabronchial; 1 mL intranasal). Animals were monitored at least twice daily throughout the
study using an established scoring sheet.30,41 Examinations were performed on days 28, 27, 25, 21, 14, 7, 0, 1, 3, 5 and 7
(euthanasia) and included clinical evaluation, thoracic radiographs, venous blood draw, and swabs. Bronchoalveolar lavage (BAL)
was performed on day 1 and 3 as described.42 The study endpoint was day 7. Following euthanasia, necropsies were performed
on all animals, and organs were harvested for virology, immunology and pathology. Gross lung lesions were scored by a board-certi-
fied veterinary pathologist blinded to the group assignment. Animals were sedatedwith either ketamine (10-12mg/Kg) or Telazol (3.5-
5mg/Kg) by intramuscular injection for all clinical examinations and procedures. Isoflurane in oxygenwas administered via facemask
as needed to maintain appropriate levels of sedation and anesthesia.
METHOD DETAILS
Biosafety and ethics
Work with infectious SARS-CoV-2 was approved by the Institutional Biosafety Committee and performed in high biocontainment at
Rocky Mountain Laboratories, NIAID, NIH. Sample removal from high biocontainment followed IBC-approved Standard Operating
Protocols. Animal work was approved by the RockyMountain Laboratories Animal Care and Use Committee and performed by certi-
fied staff in an Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility. Work
followed the institution’s guidelines for animal use, the guidelines and basic principles in the NIH Guide for the Care and Use of Lab-
oratory Animals, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy
on HumaneCare andUse of Laboratory Animals. RMswere single-housed in adjacent primate cages allowing social interactions, in a
climate-controlled room with a fixed light-dark cycle (12-hr light/12-hr dark). They were provided with commercial monkey chow,
treats, and fruit twice daily with water ad libitum. Environmental enrichment consisted of a variety of human interaction, manipulanda,
commercial toys, videos, and music.
Chimpanzee adenovirus vectors
The replication-incompetent ChAd-SARS-CoV-2-S and ChAd-Control vectors were previously described.26 Vaccines were scaled
up in HEK293 cells and purified by CsCl density-gradient ultracentrifugation. Viral particle concentration in each vector preparation
was determined by spectrophotometry at 260 nm as described.43
Neutralization assay
Serum samples were diluted serially and incubated with 102 FFU of SARS-CoV-2 for 1 h at 37C. The virus-serum mixtures
were added to Vero E6 cell monolayers in 96-well plates and incubated for 1 h at 37C. Subsequently, cells were overlaid
with 1% (w/v) methylcellulose in MEM supplemented with 2% FBS. Plates were incubated for 30 h then fixed using 4% PFA
in PBS for 1 h at room temperature. After washing, cells were sequentially incubated with murine anti-SARS-CoV-2 S mAb




and a HRP-conjugated goat anti-mouse IgG (Sigma) in PBS supplemented with 0.1% (w/v) saponin (Sigma) and 0.1% BSA.
TrueBlue peroxidase substrate (KPL) was used to develop the plates followed by counting the foci on a BioSpot analyzer
(Cellular Technology Limited).
ELISA
Purified antigens (S or RBD) were coated onto 96-well Maxisorp clear plates at 2 mg/mL in 50mMNa2CO3 pH 9.6 (70 mL) overnight at
4C. Coating buffers were aspirated, and wells were blocked with 200 mL of PBS + 0.05% Tween-20 + 5% BSA (Blocking buffer,
PBSTBA) overnight at 4C. Serum samples were diluted in PBSTBA in a separate 96-well polypropylene plate. The plates then
were washed thrice with 1X PBS + 0.05% Tween-20 (PBST) followed by addition of 50 mL of respective serum dilutions. Sera
were incubated in the ELISA plates for at least 1 h at room temperature. Plates were again washed thrice in PBST followed by addition
of 50 mL of 1:1000 goat anti-RM IgG(H+L)-HRP (Southern Biotech Cat. # 6200-05) in PBSTBA. Plates were incubated at room tem-
perature for 1 h, washed thrice in PBST, and 100 mL of 1-Step Ultra TMB-ELISA was added (ThermoFisher Cat. #34028). Reactions
were stopped with 50 mL of 2 M sulfuric acid. Optical density (450 nm) measurements were determined using a microplate reader
(Bio-Rad).
Simian Ad neutralization assays
Serum samples were collected from RMs one day prior to ChAd immunizations. Sera were serially diluted prior to incubation with 102
FFU of ChAd-SARS-CoV-2-S for 1 h at 37C. The virus-serum mixtures were added to Vero cell monolayers in 96-well plates and
incubated for 1 h at 37C. Cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented with 5% FBS. Plates were incu-
bated at 37C for 48 h before fixation with 4% PFA in PBS for 20 min at room temperature. Subsequently, plates were washed with
PBS and incubated overnight at 4Cwith murine anti-SARS-CoV-2 SmAb diluted in permeabilization buffer (PBS supplemented with
0.1% (w/v) saponin and 0.1% BSA). Plates were washed again and incubated with anti-mouse-HRP (1:500; Sigma Cat. # A9044) in
permeabilization buffer for 1 h at room temperature. After a final wash series, plates were developed using TrueBlue peroxidase sub-
strate (KPL) and foci were counted on a BioSpot analyzer (Cellular Technology Limited).
T cell assay
Peripheral blood mononuclear cells (PBMCs) were prepared by centrifugation on a Ficoll gradient. Cells (3.0 3 106 PBMCs) from
each RM were seeded into duplicate wells in a 96-well flat-bottom plate which pre-coated with human IFN-g-capturing antibody
(3.03 105 cells/well-Human IFN-g Single-Color ELISPOT-ImmunoSpot). PBMCs were stimulated with SARS-CoV-2 spike protein
peptide pools, at a final concentration of 2 mg/mL per peptide, for 24 h in a humidified incubator with 5%CO2 at 37 C. IFN-g spots
were developed according to the manufacturer’s protocol and counted by CTL 328 ImmunoSpot Analyzer and ImmunoSpot
Software.
Measurement of viral burden
SARS-CoV-2 infectedanimalswereeuthanizedatday+7after SARS-CoV-2challenge, and tissueswerecollected. Tissues (up to30mg)
were homogenized in RLT buffer. RNA was extracted using RNeasy kit (QIAGEN) according to manufacturer’s instructions. RNA was
extracted from BAL fluid and nasal swabs using the QiaAmp Viral RNA kit (QIAGEN) according to manufacturer’s instructions. SARS-
CoV-2 RNA levels were measured by one-step TaqMan RT-qPCR assay. SARS-CoV-2 nucleocapsid (N) or nsp12 specific primers
and probe sets were used: (N: F primer: ATGCTGCAATCGTGCTACAA; R primer: GACTGCCGCCTCTGCTC; probe: /56-FAM/TCAAG-
GAAC/ZEN/AACATTGCCAA/3IABkFQ/andnsp12:Fprimer:GTGARATGGTCATGTGTGGCGG;Rprimer:CARATGTTAAASACACTAT-
TAGCATA; probe 1: 6-FAM/CCAGGTGGWACRTCATCMGGTGATGC; probe 2: 6-FAM/CAGGTGGAACCTCATCAGGAGATGC. Viral
RNA was expressed as N or nsp12 gene copy numbers per g of tissues or per ml of fluid.
Virus isolation was performed on BAL liquid and homogenized lung tissues (approximately 30 mg in 1 mL DMEM using a Tissue-
Lyser (QIAGEN)) and inoculating Vero E6 cells in a 24well plate with 250 mL of cleared and a 1:10 dilution of the homogenate. One hour
after inoculation of cells, the supernatant was removed and replaced with 500 mL DMEM (Sigma-Aldrich) supplemented with 2% fetal
bovine serum, 1mM L-glutamine, 50 U/mL penicillin and 50 mg/mL of streptomycin. Six days after inoculation, cytopathogenic effect
was scored, and the TCID50 was calculated.
Histopathology and immunohistochemistry
Histopathology and immunohistochemistry were performed on RM tissues. After fixation for a minimum of 7 days in 10% neutral-
buffered formalin and embedding in paraffin, tissue sections were stained with hematoxylin and eosin (H & E). Tissues were placed
in cassettes and processed with a Sakura VIP-6 Tissue Tek on a 12-hour automated schedule, using a graded series of ethanol,
xylene, and ParaPlast Extra. Embedded tissues are sectioned at 5 mm and dried overnight at 42C prior to staining. Specific anti-
SARS-CoV-2 immunoreactivity was detected using GenScript U864YFA140-4/CB2093 NP-1 at a 1:1,000 dilution. The secondary
antibody usedwas an anti-rabbit IgG polymer from Vector Laboratories ImPress VR. Tissues were processed for immunohistochem-
istry using the Discovery Ultra automated processor (Ventana Medical Systems) with a ChromoMap DAB kit (Roche Tissue
Diagnostics).




QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was assigned when P values were < 0.05 using Prism Version 8 (GraphPad). Tests, number of animals (n),
median values, and statistical comparison groups are indicated in the Figure legends.
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Figure S1. Absence of anti-vector antibodies in RMs, Related to Fig 1. Serum samples were collected from RMs 
on day -28 prior to ChAd immunization and evaluated for neutralization activity against ChAd using a FRNT. Each 








Day 0-3 Day 4-7 
ChAd-SARS-COV-2-S 1 Pale appearance, slow, deep irregular abdominal 
respirations 
Score: 0/0/7/7 
Pale appearance, slow, deep irregular abdominal 
respirations 





3 Slightly ruffled fur, increased irregular respirations 
Score: 0/2/7/7 
Slightly ruffled fur, irregular respirations 
Score: 4/4/4/4 




5 Slightly irregular abdominal respirations 
Score:0/0/0/2 




Slightly irregular abdominal respirations 
Score: 2/0/0/0 
ChAd-Control 7 Normal 
Score:0/0/0/0 
Slightly irregular abdominal respirations 
Score: 0/2/0/2 
8 Slightly ruffled fur, slightly irregular abdominal 
respirations 
Score:0/2/4/4 
Slightly ruffled fur 
Score: 2/0/0/0 
9 Severely decreased appetite, ruffled fur, increased 
irregular abdominal respirations 
Score:0/12/12/10 
Reduced appetite, increased irregular abdominal 
respirations 
Score: 13/10/7/7 
10 Ruffled fur, increased irregular abdominal 
respirations 
Score: 0/5/5/7 
Ruffled fur, Increased irregular abdominal respirations 
score: 10/7/10/10 
11 Pale appearance, ruffled fur, increased irregular 
abdominal respirations 
Score: 0/10/10/10 
Pale appearance, slow& tired, ruffled fur, increased 
irregular abdominal respirations, elevated 
temperature on day 5&7(39.9 & 39.7 °C 
Score: 13/12/12/15 
12 Pale appearance 
Score: 0/0/0/0 
Pale appearance 
Score: 0/0/0/0 
